Sequent Scientific Limited
NSE: SEQUENT BSE: SEQUENT
NSE
206.17
2.53 (1.24%)
Prev Close
203.64
Open Price
204.7
Volume
1,087,872
Today Low / High
202.11 / 209.6
52 WK Low / High
117.35 / 231
Range
196 - 216
BSE
206.05
2.00 (0.98%)
Prev Close
204.05
Open Price
204.95
Volume
96,070
Today Low / High
202.6 / 209.5
52 WK Low / High
111 / 231.7
Range
196 - 216
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 206.17 (target range: 196 - 216), reflecting a change of 2.53 (1.24239%). On the BSE, it is listed at 206.05 (target range: 196 - 216), showing a change of 2 (0.98015%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
28 Oct
204.70
0.72%
27 Oct
202.94
0.34%
24 Oct
204.55
-1.22%
23 Oct
205.69
-1.01%
21 Oct
198.67
3.53%
20 Oct
203.00
-2.13%
17 Oct
215.80
-6.23%
16 Oct
214.90
0.11%
15 Oct
209.04
2.05%
14 Oct
220.00
-5.01%
13 Oct
216.04
0.18%
10 Oct
214.28
0.82%
09 Oct
217.00
-1.25%
08 Oct
202.00
6.68%
07 Oct
201.50
0.55%
06 Oct
204.80
-1.23%
03 Oct
194.90
3.56%
01 Oct
186.29
4.62%
30 Sep
184.10
1.19%
Sequent Scientific Limited Graph
Sequent Scientific Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Sequent Scientific Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 206.17, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 206.05 | 208.11 | 187.30 - 228.92 |
| 210.17 | 168.14 - 252.21 | ||
| 212.23 | 148.56 - 275.90 | ||
| Bearish Scenario | 206.05 | 203.99 | 183.59 - 224.39 |
| 201.93 | 161.54 - 242.31 | ||
| 199.87 | 139.91 - 259.83 |
Overview of Sequent Scientific Limited
ISIN
INE807F01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
847,885
Market Cap
51,524,532,078
Last Dividend
0
Official Website
IPO Date
2016-03-10
DCF Diff
215.37
DCF
-9
Financial Ratios Every Investor Needs
Stock Dividend of SEQUENT
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2021-09-08 | September 08, 21 | 0.5 | 0.5 | 2021-09-10 | 2021-10-21 | |
| 2019-08-21 | August 21, 19 | 0.2 | 0.2 | 2019-08-22 | 2019-09-28 | 2019-05-14 |
| 2017-11-20 | November 20, 17 | 0.2 | 0.2 | 2017-11-21 | 2017-12-04 | 2017-11-09 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,551.37 Cr | 811.85 Cr | 739.52 Cr | 0.4767 | 0.00 Cr | 55.15 Cr | 458.40 Cr | 21.88 Cr | 0.88 | 158.86 Cr | 0.0141 |
| 2024-03-31 | 1,366.30 Cr | 813.12 Cr | 553.19 Cr | 0.4049 | 0.00 Cr | 55.36 Cr | 37.02 Cr | -35.87 Cr | -1.44 | 54.98 Cr | -0.0263 |
| 2023-03-31 | 1,418.28 Cr | 1,259.55 Cr | 158.72 Cr | 0.1119 | 0.00 Cr | 54.03 Cr | -9.74 Cr | -121.16 Cr | -4.88 | -46.45 Cr | -0.0854 |
| 2022-03-31 | 1,410.17 Cr | 844.44 Cr | 565.74 Cr | 0.4012 | 0.00 Cr | 50.03 Cr | 67.40 Cr | 40.96 Cr | 1.66 | 117.98 Cr | 0.0290 |
| 2021-03-31 | 1,352.04 Cr | 736.56 Cr | 615.47 Cr | 0.4552 | 0.00 Cr | 45.51 Cr | 155.01 Cr | 95.44 Cr | 3.87 | 206.48 Cr | 0.0706 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 69.07 Cr | 1,601.95 Cr | 831.59 Cr | 704.4700 Cr | 481.25 Cr | 412.18 Cr | 385.32 Cr | 299.43 Cr | 0.00 Cr | 0.00 Cr | 0.01 Cr | 505.0100 Cr |
| 2024-03-31 | 64.81 Cr | 1,540.38 Cr | 827.43 Cr | 656.5600 Cr | 487.69 Cr | 422.88 Cr | 346.23 Cr | 311.23 Cr | 8.13 Cr | 0.00 Cr | 4.43 Cr | 626.9900 Cr |
| 2023-03-31 | 41.57 Cr | 1,529.12 Cr | 779.93 Cr | 698.7780 Cr | 443.60 Cr | 402.02 Cr | 346.09 Cr | 352.13 Cr | -0.56 Cr | 0.00 Cr | 3.54 Cr | 558.7580 Cr |
| 2022-03-31 | 57.50 Cr | 1,450.97 Cr | 710.87 Cr | 692.0982 Cr | 364.90 Cr | 307.40 Cr | 347.97 Cr | 325.34 Cr | 3.36 Cr | 0.00 Cr | 36.79 Cr | 512.1210 Cr |
| 2021-03-31 | 53.74 Cr | 1,392.56 Cr | 616.24 Cr | 727.6510 Cr | 276.98 Cr | 223.24 Cr | 264.36 Cr | 347.86 Cr | 0.00 Cr | 0.00 Cr | 76.94 Cr | 460.0170 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 83.3600 Cr | -24.7800 Cr | -60.7300 Cr | 44.2700 Cr | -2.1500 Cr | 62.6600 Cr | -39.0900 Cr | 21.8800 Cr | -2.6000 Cr | 0.0000 Cr | -46.8600 Cr |
| 2024-03-31 | 30.5950 Cr | -11.9050 Cr | 4.5460 Cr | -0.2120 Cr | 23.2360 Cr | 64.8100 Cr | -30.8070 Cr | -35.8690 Cr | 54.8070 Cr | 0.0000 Cr | 0.2860 Cr |
| 2023-03-31 | 16.8080 Cr | -64.9580 Cr | 32.2280 Cr | -69.3710 Cr | -15.9220 Cr | 41.5740 Cr | -86.1790 Cr | -137.6580 Cr | 77.6690 Cr | 0.0000 Cr | 5.0790 Cr |
| 2022-03-31 | 30.5950 Cr | -95.5660 Cr | 67.2570 Cr | -1.8690 Cr | 3.7520 Cr | 57.4960 Cr | -32.4640 Cr | 52.9300 Cr | 91.1120 Cr | -12.3440 Cr | -114.7330 Cr |
| 2021-03-31 | 114.7540 Cr | 9.6480 Cr | -138.7540 Cr | 61.9240 Cr | -14.3520 Cr | 53.7440 Cr | -52.8300 Cr | 145.4520 Cr | -117.4150 Cr | 0.0000 Cr | -45.6170 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 441.42 Cr | 234.55 Cr | 206.87 Cr | 0.4686 | 33.35 Cr | 14.31 Cr | 0.57 | 54.81 Cr | 0.0324 |
| 2025-03-31 | 401.70 Cr | 199.74 Cr | 201.96 Cr | 0.5028 | 125.15 Cr | 9.32 Cr | 0.37 | 46.09 Cr | 0.0232 |
| 2024-12-31 | 390.81 Cr | 202.53 Cr | 188.28 Cr | 0.4818 | 16.98 Cr | 3.44 Cr | 0.14 | 40.03 Cr | 0.0088 |
| 2024-09-30 | 368.65 Cr | 195.29 Cr | 173.36 Cr | 0.4703 | 19.47 Cr | 2.61 Cr | 0.11 | 39.29 Cr | 0.0071 |
| 2024-06-30 | 390.21 Cr | 214.29 Cr | 175.92 Cr | 0.4508 | 113.87 Cr | 6.51 Cr | 0.26 | 44.63 Cr | 0.0167 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 63.08 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -770.36 Cr |
| 2025-03-31 | 69.07 Cr | 0.42 Cr | 69.14 Cr | 363.17 Cr | 385.32 Cr | 873.73 Cr | 299.43 Cr | 1,601.95 Cr | 831.59 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 74.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -741.87 Cr |
| 2024-09-30 | 74.12 Cr | 0.14 Cr | 74.26 Cr | 341.22 Cr | 361.48 Cr | 828.95 Cr | 306.00 Cr | 1,562.05 Cr | 820.18 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 72.44 Cr | 0.00 Cr | 0.00 Cr | 72.44 Cr | 0.00 Cr | 0.00 Cr | -712.96 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 14.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 9.32 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 3.44 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 2.61 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 6.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,687.00 | ₹4,047,671,982,389.00 | ₹2,440,907.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,438.50 | ₹1,709,224,809,162.00 | ₹305,872.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,576.50 | ₹1,210,448,542,500.00 | ₹133,893.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,289.40 | ₹1,073,250,238,305.00 | ₹1,828,269.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,001.25 | ₹1,007,487,347,951.00 | ₹382,044.00 |
| Mankind Pharma Limited | MANKIND | ₹2,406.50 | ₹993,303,306,185.00 | ₹271,023.00 |
| Lupin Limited | LUPIN | ₹1,918.70 | ₹876,381,321,332.00 | ₹668,996.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,432.00 | ₹649,477,080,000.00 | ₹156,752.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,099.40 | ₹638,533,304,326.00 | ₹1,130,406.00 |
| Laurus Labs Limited | LAURUSLABS | ₹959.65 | ₹518,042,964,325.00 | ₹2,714,923.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,815.10 | ₹512,222,688,416.00 | ₹339,123.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹859.70 | ₹328,892,970,258.00 | ₹338,239.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,285.90 | ₹326,238,253,926.00 | ₹63,010.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,388.40 | ₹298,396,244,362.00 | ₹56,805.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,686.00 | ₹264,021,258,954.00 | ₹36,351.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,315.50 | ₹232,887,500,000.00 | ₹17,491.00 |
| Eris Lifesciences Limited | ERIS | ₹1,628.40 | ₹221,810,151,334.00 | ₹201,101.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,296.90 | ₹210,726,538,417.00 | ₹240,869.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,740.00 | ₹201,942,452,860.00 | ₹26,058.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹905.60 | ₹178,007,565,094.00 | ₹64,648.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,122.00 | ₹177,893,979,648.00 | ₹220,240.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,012.00 | ₹152,935,532,352.00 | ₹30,388.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹826.50 | ₹148,034,307,555.00 | ₹240,008.00 |
| Granules India Limited | GRANULES | ₹569.95 | ₹138,309,034,684.00 | ₹457,943.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,183.00 | ₹102,633,978,906.00 | ₹5,459.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹843.00 | ₹76,403,592,867.00 | ₹103,602.00 |
| Strides Pharma Science Limited | STAR | ₹814.00 | ₹75,028,589,196.00 | ₹168,130.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹361.10 | ₹70,624,593,758.00 | ₹144,078.00 |
| FDC Limited | FDC | ₹432.05 | ₹70,342,096,792.00 | ₹151,149.00 |
| Sequent Scientific Limited | SEQUENT | ₹206.17 | ₹51,524,532,078.00 | ₹1,087,872.00 |
| Innova Captab Limited | INNOVACAP | ₹809.85 | ₹46,343,608,751.00 | ₹13,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹142.23 | ₹46,156,705,461.00 | ₹7,842,918.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹481.10 | ₹43,909,997,000.00 | ₹215,251.00 |
| Suven Life Sciences Limited | SUVEN | ₹194.00 | ₹42,299,895,218.00 | ₹85,389.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,377.50 | ₹39,321,508,163.00 | ₹8,656.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹703.85 | ₹35,698,642,054.00 | ₹75,131.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹337.35 | ₹33,830,303,399.00 | ₹45,042.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹465.55 | ₹32,777,396,913.00 | ₹10,150.00 |
| Hikal Limited | HIKAL | ₹239.90 | ₹29,579,849,925.00 | ₹123,352.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹92.69 | ₹27,207,064,902.00 | ₹1,021,951.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹48.35 | ₹26,493,561,347.00 | ₹906,733.00 |
Key Executives
Vice President of HR & Administration
Mr. Prasad Lad
Gender: male
Year Born:
Chief Financial Officer
Mr. Saurav Bhala
Gender: male
Year Born:
Executive Vice President of Human Resources & Administration
Mr. Ravi Nair
Gender: male
Year Born:
MD, Chief Executive Officer & Director
Mr. Rajaram Narayanan
Gender: male
Year Born: 1968
Executive Director
Mr. Vedprakash Ragate
Gender: male
Year Born:
Company Secretary & Compliance Officer
Ms. Yoshita Vora
Gender: female
Year Born:
Corporate Vice President of Ra Qa and Technical Services
Mr. Ramesh Kumar Pillai
Gender: male
Year Born: 1965
Head of Investor Relations
Mr. Abhishek Singhal
Gender: male
Year Born:
Assoc. Vice President, Head of Legal & Chief Risk Officer
Mr. Phillip Trott
Gender: male
Year Born:
FAQs about Sequent Scientific Limited
Who is the CEO of the company?
The CEO is Rajaram Narayanan.
What is the current market price of the stock?
The current price is ₹206.17.
What is the 52-week price range?
The range is ₹117.35-231.
What is the market capitalization of the company?
The market capitalization is ₹5,152.45 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 174.39.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Sequent Scientific Limited (ISIN: INE807F01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹5,152.45 crores and an average daily volume of 847,885 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.